Circulating Tumor Cells (CTC) in Cancer
1 other identifier
observational
3,000
1 country
2
Brief Summary
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 5, 2020
CompletedFirst Posted
Study publicly available on registry
August 20, 2020
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2030
March 12, 2025
March 1, 2025
9.8 years
August 5, 2020
March 10, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Overall survival (OS) in heterogeneous cancer population
overall survival (OS) in heterogeneous cancer population
Screening (Visit 1) until the date of death (assessed up to 240 months)
Change in total number of isolated CTCs
Change in total number of isolated CTCs
Through study completion, an average of 20 years
Secondary Outcomes (1)
Progression free survival (PFS)
Through study completion, an average of 20 years
Other Outcomes (1)
Change in circulating tumor DNA (ctDNA) from blood samples
Through study completion, an average of 20 years
Interventions
Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
Eligibility Criteria
adult patients (\> 18 years) with a cancer diagnosis
You may qualify if:
- Adult cancer patients
- All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
- All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
- Written pathology report must be available.
- Written informed consent.
You may not qualify if:
- No written informed consent.
- No proved diagnosis of malignancy by pathology report.
- Patients with the diagnosis of blood cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
University Hospital Basel
Basel, 4031, Switzerland
Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
Liestal, 4410, Switzerland
Biospecimen
CTC cultures stored in the refrigerator. A "Biobank Reglement" is enclosed to this protocol.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marcus Vetter, PD Dr. med.
Kantonsspital Baselland, Liestal
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 5, 2020
First Posted
August 20, 2020
Study Start
October 1, 2020
Primary Completion (Estimated)
August 1, 2030
Study Completion (Estimated)
August 1, 2030
Last Updated
March 12, 2025
Record last verified: 2025-03